Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR(r) in Canada

Veloxis Announces U.S. FDA Approval of Envarsus® XR for Treatment of Kidney Transplant Patients

Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients

U.S. District Court Rules in Veloxis Litigation

Warrant Programme – Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants

Veloxis Pharmaceuticals announces financial results for the first three months of 2015

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the first Quarter 2015 – results from 1 January to 31 March, 2015

Envarsus® XR Demonstrates Improved Pharmacokinetic Profile in African-American Transplant Recipients

Warrant Programme – New Articles of Association

Veloxis Pharmaceuticals A/S establishes new Warrant Programme

Warrant Programme – Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants

Veloxis Pharmaceuticals A/S – Passing of Annual General Meeting

Notice to Convene Annual General Meeting

Warrant Programme – New Articles of Association

Veloxis Pharmaceuticals A/S establishes new Warrant Programme

Veloxis Pharmaceuticals publishes Annual Report 2014

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2014 – results from 1 January to 31 December, 2014

Veloxis Pharmaceuticals Announces Updated Financial Calendar for 2015

U.S. District Court Sets Briefing Schedule in Veloxis Litigation

Veloxis Confirms Receipt of U.S. Food and Drug Administration Decision

Veloxis Comments on U.S. District Court Order

Veloxis announces that it has filed an action against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.

Veloxis Pharmaceuticals Announces Financial Calendar for 2015

Veloxis Announces Publication of Phase III Study of Once Daily Envarsus® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients

Warrant Programme – New Articles of Association

Veloxis Pharmaceuticals A/S establishes new Warrant Programme

Veloxis Pharmaceuticals announces financial results for the first nine months of 2014 and improves the full year outlook

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2014 – results from 1 January to 30 September, 2014

Veloxis Pharmaceuticals A/S to Host Conference Call discussing the FDA tentative approval of Envarsus® XR

Veloxis announces tentative approval of Envarsus® XR